Skip Navigation


European Heart Journal Advance Access originally published online on February 28, 2007
European Heart Journal 2007 28(6):653-654; doi:10.1093/eurheartj/ehl566
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/6/653    most recent
ehl566v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Meier, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meier, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

(Active) stents are no panacea, a déjà-vu

Bernhard Meier

Cardiovascular Department, University Hospital Bern, Bern 3010, Switzerland

Corresponding author. Tel: +41 31 632 30 77; fax: +41 31 382 10 69. E-mail address: bernhard.meier@insel.ch

This editorial refers to ‘Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)’ {dagger} by H-P. Brunner-La Rocca et al., on page 719

The first 10% of the full text of this article appears below.

Bare metal stents (BMS) and drug-eluting stents (DES) were and are going through similar cycles, albeit in reverse order. BMS went through an initial bashing period only to come out of it worshiped more than really deserved. The opposite happened to DES. They are currently going through their bashing period after having been hailed in as prodigies they not really were. The paper of the Basel group is a first commendable effort to put things back into the places they really belong.1

BMS first went through an undeserved period of bad reputation (particularly in the US) because their results were not properly adjusted for the baseline situation. Introduced to prevent abrupt closure in the first place, BMS were initially used exclusively for failed balloon angioplasty cases. Although it was soon known that they also . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Hans-Peter Brunner-La Rocca, Christoph Kaiser, Matthias Pfisterer, and on behalf of the BASKET Investigators
EHJ 2007 28: 719-725. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
S. D. Kristensen, H. Baumgartner, H. Drexler, E. Eeckhout, G. Filippatos, A. K. Gitt, C. Linde, L. A. Pierard, D. Poldermans, H. Schunkert, et al.
Highlights of the 2007 Scientific Sessions of the European Society of Cardiology: Vienna, Austria, September 1 5, 2007
J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2421 - 2430.
[Full Text] [PDF]

Home page
 CirculationHome page
S. Windecker and B. Meier
Late Coronary Stent Thrombosis
Circulation, October 23, 2007; 116(17): 1952 - 1965.
[Full Text] [PDF]